Castle Biosciences, Inc.

Equities

CSTL

US14843C1053

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
18.55 ^USD	+0.32%		+6.61%	-14.04%

Jun. 24	Castle Biosciences, Inc. Announces that AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences? TissueCypher Test	CI
May. 30	Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology	CI

Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2021

January 10, 2022 at 07:04 am EST

Castle Biosciences, Inc. provided revenue guidance for the full year 2021. The Company expects to meet or exceed the top end of previously guided range of $89 million - $93 million for full-year 2021 revenue.

Latest news about Castle Biosciences, Inc.

Castle Biosciences, Inc. Announces that AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences? TissueCypher Test	Jun. 24	CI
Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology	May. 30	CI
Castle Biosciences, Inc. Announces That New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis	May. 29	CI
Castle Biosciences Insider Sold Shares Worth $574,679, According to a Recent SEC Filing	May. 08	MT
Castle Biosciences, Inc. Announces New Data from A Study Further Confirming the Performance of its DecisionDx-UM Test as A Robust Independent Predictor of Metastasis-Free Survival in Patients Diagnosed with UM	May. 08	CI
Transcript : Castle Biosciences, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q1 Revenue $73M, vs. Street Est of $66.2M	May. 02	MT
Castle Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024	May. 02	CI
Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing	Apr. 08	MT
Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress	Apr. 04	CI
Castle Biosciences, Inc. Announces Board Changes	Mar. 27	CI
Castle Biosciences, Inc. Announces the Publication of an Expert Consensus Article in the Journal of Clinical and Aesthetic Dermatology	Mar. 19	CI
Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test	Mar. 07	CI
Transcript : Castle Biosciences, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q4 Revenue $66.1M, vs. Street Est of $61.2M	Feb. 28	MT
Castle Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024	Feb. 28	CI
Castle Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Castle Biosciences Insider Sold Shares Worth $493,818, According to a Recent SEC Filing	Feb. 07	MT
Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii	Jan. 14	CI
Castle Biosciences Insider Sold Shares Worth $475,585, According to a Recent SEC Filing	Jan. 08	MT
Castle Biosciences Sees 53% Growth in Annual Revenue in 2023	Jan. 08	MT
Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023	Jan. 07	CI
Castle Biosciences Insider Sold Shares Worth $301,774, According to a Recent SEC Filing	Dec. 29	MT

Chart Castle Biosciences, Inc.

Duration

Period

More charts

Company Profile

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Castle Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

18.55 USD

Average target price

34.33 USD

Spread / Average Target

+85.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
CASTLE BIOSCIENCES, INC.	-14.04%	512M
BIOMÉRIEUX	-4.72%	12.35B
LANTHEUS HOLDINGS, INC.	+99.06%	8.55B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-22.10%	6.6B
DIASORIN S.P.A.	+8.48%	5.88B
AUTOBIO DIAGNOSTICS CO., LTD.	-22.96%	3.52B
ANDON HEALTH CO., LTD.	+6.08%	2.55B
MYRIAD GENETICS, INC.	+38.04%	2.39B
VITROLIFE AB	-7.04%	2.33B
10X GENOMICS, INC.	-68.75%	2.09B

Diagnostic & Testing Substances